At present, MGT-based blood group test card has been used extensively in the field of blood typing, and MGT boasts of easy operation, high sensitivity, accurate results that can be saved and other strengthens, which allowed it to become method recommended by American Association of Blood Banks (AABB), technique recognized by FDA and internationally recognized blood group analysis test technique.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced a strategic collaboration with NVIDIA to power AI-based solutions and laboratory automation at scale. The effort will leverage the NVIDIA Artificial Intelligence (AI) platform and Thermo Fisher Scientific solutions to progressively increase the automation, accuracy and speed of laboratories.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced select, preliminary, unaudited results for the fourth quarter and full year ended December 31, 2025.

NAMSA, a global leader in medical device testing, clinical research, and regulatory consulting, is pleased to announce it has completed the acquisition of the Early Development medical device testing business of Labcorp (NYSE: LH), a leading provider of innovative and comprehensive laboratory services. This strategic move underscores NAMSA's commitment to advancing innovation and accelerating time-to-market for MedTech manufacturers worldwide.

Cardiovascular testing firm Prevencio and Quadrant Health said Thursday that they have entered an agreement to integrate Prevencio's HART CVE and HART CADhs blood tests into Quadrant's primary care workflows to better translate the test results into clinical action and measure outcomes.

US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of more than $20bn in what would be the latest big deal in the red-hot biotechnology sector.

MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), today announced the successful completion of the cash tender offer, through a subsidiary, for all the outstanding shares of common stock of Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”).

SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration that unites SOPHiA GENETICS' AI-powered analytics with MD Anderson's clinical and scientific expertise to accelerate data-driven cancer care through new tools that can accurately analyze, interpret and translate diagnostic results into clinical practice.

National Health Commission of the PRC recently convened a meeting in Beijing to outline ten practical initiatives for public service by 2026.

Adaptive Biotechnologies said last week that its new subsidiary Digital Biotechnologies has held an initial closing of its Series A preferred stock financing and expects to raise up to $15 million in the round.

Mdxhealth and the University of Oxford will test whether the firm's Genomic Prostate Score (GPS) assay can predict disease progression and treatment outcomes in prostate cancer patients, the company said Tuesday.